Study guide
3.6 Valvular Heart Disease: Stenosis & Regurgitation
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
3.6 Valvular Heart Disease: Stenosis & Regurgitation
Key Takeaways Explain This Topic AI
Aortic Stenosis presents with the classic clinical triad of Angina, Syncope, and Heart Failure ('SAD'), featuring a crescendo-decrescendo systolic murmur and severe threshold criteria of AVA <1.0 cm².
Severe Aortic Regurgitation is characterized by a widened pulse pressure, Water-hammer pulse, and Austin Flint murmur, requiring afterload reduction and timely surgical replacement before LV dilation becomes irreversible.
Mitral Stenosis is predominantly caused by Rheumatic Heart Disease, presenting with an opening snap, mid-diastolic rumble, progressive LA enlargement, and heightened risk for atrial fibrillation and systemic thromboembolism.
Acute Mitral Regurgitation secondary to post-MI papillary muscle rupture presents with sudden catastrophic pulmonary edema and cardiogenic shock requiring urgent surgical repair or MitraClip.
Mechanical valve prostheses require lifelong systemic anticoagulation with Warfarin (Target INR 2.5–3.5 for mitral, 2.0–3.0 for aortic), whereas bioprosthetic tissue valves require only short-term anticoagulation.
Last updated: August 2026
3.6 Valvular Heart Disease: Stenosis & Regurgitation
Valvular heart disease involves structural stenosis (failure of a valve to open fully, increasing pressure workload) or regurgitation/insufficiency (failure of a valve to close completely, causing blood backflow and volume overload). Understanding valvular hemodynamics, characteristic auscultatory murmurs, diagnostic criteria, and advanced interventional therapies (SAVR, TAVR, MitraClip) is vital for the AACN Cardiac Medicine Certification.
- Aortic Valve Disorders
- Aortic Stenosis (AS)
Etiology: Age-related calcific degeneration (most common in adults >70 years), congenital bicuspid aortic valve (presents earlier, ages 40–60), or rheumatic heart disease.
Pathophysiology: Chronic obstruction to LV outflow forces the left ventricle to generate massive systolic pressures, leading to severe concentric LV hypertrophy . Hypertrophy reduces LV compliance, raising end-diastolic pressure and impairing coronary perfusion.
Classic Clinical Triad ("SAD"):
S - Syncope: Exertional syncope due to fixed cardiac output unable to meet peripheral exercise vasodilation.
A - Angina: Myocardial ischemia from extreme muscle mass demand exceeding coronary supply.
D - Dyspnea / Heart Failure: Exertional dyspnea progressing to overt pulmonary edema.
Auscultation & Peripheral Exam:
Murmur: Harsh crescendo-decrescendo systolic ejection murmur , best heard at the right 2nd intercostal space, radiating to the carotid arteries.
Pulsus Parvus et Tardus: Carotid pulse is weak (parvus) and delayed (tardus).
S2 Changes: Single S2 or paradoxically split S2 (A2 delayed behind P2).
Diagnostic Thresholds for Severe AS:
Aortic Valve Area (AVA): < 1.0 cm² (or AVA index < 0.6 cm²/m²).
Mean Pressure Gradient: > 40 mmHg .
Peak Jet Velocity: > 4.0 m/s .
Nursing Priorities & Interventions:
Avoid Hypotension & Preload Depletion: Patients with severe AS are strictly preload-dependent. Vasodilators (ACEi, nitrates) and vigorous diuresis must be used with extreme caution to prevent circulatory collapse.
Intervention Timing: Indicated for any symptomatic severe AS, or asymptomatic severe AS with LVEF < 50%. Options include Surgical Aortic Valve Replacement (SAVR) or Transcatheter Aortic Valve Replacement (TAVR) .
Aortic Regurgitation (AR)
Etiology: Leaflet damage (infective endocarditis, rheumatic fever) or aortic root dilation (aortic dissection, Marfan syndrome, severe HTN).
Pathophysiology: Blood regurgitates from the aorta into the LV during diastole. The LV undergoes massive eccentric hypertrophy and dilation to accommodate both normal atrial inflow and regurgitant volume ("cor bovinum" / massive heart).
Acute vs. Chronic AR:
Acute AR: Normal-sized, non-compliant LV is overwhelmed by sudden volume. Presents as catastrophic cardiogenic shock and pulmonary edema. Immediate surgical emergency!
Chronic AR: LV adaptively dilates over decades, remaining asymptomatic until severe LV dysfunction develops.
Physical Exam Hallmarks:
Widened Pulse Pressure: High systolic BP with extremely low diastolic BP (e.g., 160/45 mmHg).
Corrigan's / Water-Hammer Pulse: Bounding arterial pulse with rapid stroke rise and sudden collapse.
Auscultation: High-pitched, decrescendo early diastolic murmur at the left sternal border. Austin Flint Murmur: Low-pitched mid-diastolic rumble at the apex, caused by the regurgitant aortic jet striking the anterior mitral leaflet.
Management: Surgical aortic valve replacement is the definitive therapy. The 2020 ACC/AHA valvular guideline dropped the older "vasodilator as a bridge to surgery" recommendation — nifedipine to delay surgery is no longer current practice. Medical therapy is now limited to treating hypertension (systolic > 140 mmHg) in asymptomatic disease, and guideline-directed therapy with an ACE inhibitor/ARB or sacubitril-valsartan in symptomatic severe AR with LV dysfunction when surgical risk is prohibitive . Transcatheter therapy for pure native AR remains off-label in general practice (the 2020 guideline gives it a Class 3), though a dedicated device received FDA approval in March 2026 for high-surgical-risk symptomatic severe AR.
Loading diagram... Valvular Heart Disease: Hemodynamic Impact and Auscultatory Signatures
- Mitral Valve Disorders
- Mitral Stenosis (MS)
Etiology: Overwhelmingly caused by Rheumatic Heart Disease (post-streptococcal autoimmune cross-reactivity) resulting in commissural fusion and leaflet thickening ("fish-mouth" valve orifice).
Pathophysiology: Obstruction of blood flow from the left atrium into the left ventricle during diastole leads to elevated Left Atrial (LA) pressures, progressive LA enlargement , and backward transmission into the pulmonary vasculature, causing secondary pulmonary arterial hypertension and right ventricular failure.
Complications:
Atrial Fibrillation: Marked LA stretch triggers AF in up to 50% of patients. Loss of atrial kick combined with rapid heart rate drastically impairs diastolic LV filling, causing sudden hemodynamic collapse.
Systemic Thromboembolism: LA stasis combined with AF creates an extremely high risk for mural thrombus formation and stroke.
Auscultation: Loud S1, followed by a high-pitched Opening Snap (OS) in early diastole, followed by a low-pitched mid-diastolic rumble best heard at the apex in the left lateral decubitus position with the bell.
Diagnostic Thresholds: Severe MS is defined as Mitral Valve Area (MVA) ≤ 1.5 cm² .
Management: Rate control (beta-blockers, non-DHP CCBs) to prolong diastolic filling time. Mandatory Anticoagulation (Warfarin) for MS with Afib. Interventions include Percutaneous Transvenous Mitral Commissurotomy (PTMC / Balloon Valvuloplasty) or surgical replacement.
Mitral Regurgitation (MR)
Etiology: Primary/Organic (Mitral Valve Prolapse [MVP], chordae tendineae rupture, infective endocarditis) or Secondary/Functional (LV dilation stretching the mitral annulus in dilated or ischemic cardiomyopathy).
Acute MR (Post-MI Papillary Muscle Rupture):
Occurs 2 to 7 days post-MI (most commonly inferior MI affecting the posteromedial papillary muscle , which has a single blood supply from the Posterior Descending Artery).
Manifests as abrupt, catastrophic pulmonary edema, hypotension, hyperdynamic apical impulse, and a soft holosystolic murmur .
Emergency Management: Intra-aortic balloon pump (IABP) or Impella support to reduce afterload and regurgitant volume, alongside immediate emergency surgical valve repair/replacement.
Chronic MR:
Asymptomatic for years due to progressive LA and LV enlargement. Leads to eventual LV systolic failure.
Auscultation: Blowing holosystolic (pansystolic) murmur at the cardiac apex radiating into the left axilla.
Interventions: Surgical Mitral Valve Repair (preferred over replacement). For high surgical risk patients, Transcatheter Edge-to-Edge Repair (TEER / MitraClip) clips the anterior and posterior leaflets together to reduce regurgitation.
- Tricuspid & Pulmonic Valve Disorders
- Tricuspid Regurgitation (TR)
Etiology: Most commonly functional/secondary to Right Ventricular dilation and pulmonary hypertension; primary causes include infective endocarditis (in intravenous drug users) and pacemaker lead damage.
Physical Exam: Prominent 'v' wave in jugular venous pulsations, holosystolic murmur at the lower left sternal border that increases with inspiration (Carvallo's sign) , hepatomegaly with pulsatile liver, ascites, and peripheral edema.
Pulmonic Valve Disorders
Pulmonic Stenosis (PS): Almost exclusively congenital (Tetralogy of Fallot, Noonan syndrome). Auscultation reveals a systolic ejection murmur at the left upper sternal border with an ejection click.
Pulmonic Regurgitation (PR): Most commonly secondary to severe pulmonary arterial hypertension, producing a high-pitched early diastolic decrescendo murmur ( Graham Steell murmur ).
Prosthetic Valve Selection & Nursing Management
When native valve repair is unfeasible, valve replacement is performed using either mechanical or bioprosthetic tissue valves.
Valve Type Materials & Design Structural Durability Anticoagulation Requirement Ideal Patient Candidates
Mechanical Valves Pyrolytic carbon / bileaflet design Lifetime durability (> 20–30 years); low structural failure Lifelong Systemic Anticoagulation (Warfarin) mandatory Younger patients (<65 years); patients already taking long-term anticoagulation
Bioprosthetic Valves Bovine pericardium or porcine leaflets Limited durability ( 10–15 years ); prone to calcification Short-term anticoagulation (3 months Aspirin ± Warfarin); no lifelong anticoagulation Older patients (>65–70 years); high bleeding risk; women planning pregnancy
Target INR Ranges for Mechanical Valves
Mechanical Aortic Valve: Target INR 2.0 – 3.0 .
Mechanical Mitral Valve (or Aortic with risk factors): Target INR 2.5 – 3.5 (higher thromboembolic risk due to lower velocity flow across the mitral position).
Post-Procedure Nursing Priorities (TAVR & MitraClip)
Vascular Access Monitoring: Transfemoral access sites require frequent vascular checks to detect hematoma formation, retroperitoneal hemorrhage (sudden flank pain, hypotension, tachycardia), or pseudoaneurysm.
Conduction Disturbances (Post-TAVR): The aortic valve lies in close anatomical proximity to the AV node and bundle of His. Balloon expansion can cause new high-grade AV block or LBBB , requiring continuous cardiac monitoring and frequent permanent pacemaker placement.
Stroke Monitoring: Thromboembolic debris liberated during valve deployment requires immediate post-procedure neurological assessments (NIHSS).